The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of XL184 (cabozantinib) plus erlotinib in patients (pts) with advanced EGFR-mutant non-small cell lung cancer (NSCLC) with progressive disease (PD) on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy: A California Cancer Consortium phase II trial (NCI 9303).
Karen L. Reckamp
Consultant or Advisory Role - Boehringer Ingelheim
Research Funding - Astellas Pharma
Paul Henry Frankel
No relevant relationships to disclose
Philip C Mack
No relevant relationships to disclose
Barbara Jennifer Gitlitz
Honoraria - Genentech
Nora Ruel
No relevant relationships to disclose
Primo Lara
Consultant or Advisory Role - Exelixis; Genentech
Tianhong Li
No relevant relationships to disclose
Marianna Koczywas
No relevant relationships to disclose
Shirish M. Gadgeel
Consultant or Advisory Role - Genentech
Mihaela C. Cristea
No relevant relationships to disclose
Chandra Prakash Belani
No relevant relationships to disclose
Edward M. Newman
No relevant relationships to disclose
David R. Gandara
Consultant or Advisory Role - Exelixis
Research Funding - Genentech